Related Experiment Video
Updated: Jul 17, 2025

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
Published on: April 20, 2018
Management of clinically node-negative early-stage oral cancer: network meta-analysis of randomized clinical trials
E A Al-Moraissi1, A S Alkhutari1, R de Bree2
1Department of Oral and Maxillofacial Surgery, Thamar University, Thamar, Yemen.
Abstract:
The best treatments for the clinically node-negative (cN0) neck in early-stage oral squamous cell carcinoma (OSCC) patients are a subject of ongoing debate and there is no consensus. A network meta-analysis (NMA) of randomized clinical trials (RCTs) was conducted to determine the most effective treatment and to rank treatments based on their effectiveness. A systematic search was performed in accordance with the PRISMA guidelines to retrieve RCTs that compared therapeutic neck dissection (TND), sentinel lymph node biopsy (SLNB), and elective neck dissection (END). The outcomes analysed were overall survival (OS), disease-specific survival (DSS), disease-free survival (DFS), and nodal recurrence. Hazard ratios and risk ratios were calculated by direct meta-analysis and NMA. Ten RCTs with a total of 1858 patients were eligible for inclusion. Direct meta-analysis showed END to be superior to TND and comparable to SLNB. The NMA revealed no statistically significant difference between END and SLNB (very low quality evidence) regarding OS, DSS, DFS, and nodal recurrence. However, END was found to significantly improve OS and DFS, and reduce nodal recurrence when compared to TND (moderate quality evidence). END ranked as probably the top treatment option for maximizing OS and DSS, and reducing nodal recurrence in early-stage OSCC, followed by SLNB and TND. There was very low quality evidence supporting SLNB as non-inferior to END for patients with early-stage OSCC. This NMA yielded favourable results for the use of END (with moderate quality evidence) in early-stage OSCC patients, although excellent results have also been obtained with SLNB. However, data in the literature for SLNB are scarce, as this technique has not yet been formalized in many countries. There is a need to further explore SLNB for early-stage OSCC patients, as well as its value in detecting occult lymph node metastases on the contralateral side. More studies comparing morbidity, quality of life, and costs between the different management strategies for the clinically negative neck in early-stage OSCC patients are needed.
Insights
Elective neck dissection (END) is likely the best treatment for early-stage oral squamous cell carcinoma (OSCC) with a clinically node-negative neck, offering improved survival and reduced recurrence compared to therapeutic neck dissection (TND). Sentinel lymph node biopsy (SLNB) shows comparable results to END but requires further research.
Area of Science:
- Oncology
- Surgical Oncology
- Head and Neck Surgery
Background:
- Optimal management of the clinically node-negative (cN0) neck in early-stage oral squamous cell carcinoma (OSCC) lacks consensus.
- Existing treatment options include therapeutic neck dissection (TND), sentinel lymph node biopsy (SLNB), and elective neck dissection (END).
Purpose of the Study:
- To conduct a network meta-analysis (NMA) of randomized clinical trials (RCTs) to determine the most effective treatment for the cN0 neck in early-stage OSCC.
- To rank treatments based on effectiveness for overall survival (OS), disease-specific survival (DSS), disease-free survival (DFS), and nodal recurrence.
Main Methods:
- A systematic literature search adhering to PRISMA guidelines identified relevant RCTs comparing TND, SLNB, and END.
- Direct meta-analysis and NMA were performed to calculate hazard ratios and risk ratios for key outcomes.
- Ten RCTs involving 1858 patients were included in the analysis.
Main Results:
- Direct meta-analysis indicated END was superior to TND and comparable to SLNB.
- NMA showed no significant difference between END and SLNB for OS, DSS, DFS, and nodal recurrence (very low quality evidence).
- END significantly improved OS and DFS, and reduced nodal recurrence compared to TND (moderate quality evidence). END ranked highest, followed by SLNB and TND.
Conclusions:
- Elective neck dissection (END) is a favorable treatment for the cN0 neck in early-stage OSCC, supported by moderate-quality evidence.
- Sentinel lymph node biopsy (SLNB) shows promise but requires more extensive research, particularly regarding its efficacy in detecting contralateral metastases and its long-term outcomes.
- Further studies are needed to compare the morbidity, quality of life, and costs associated with different neck management strategies in early-stage OSCC.
More Related Videos
Related Concept Videos
Cancer Survival Analysis
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers
Clinical Trials
There are four phases in a clinical trial. A phase one...

